恩替卡韦 (ETV) 是病毒复制的一种强效抑制剂，但是仅少数HBeAg阳性的慢性乙型肝炎(CHB) 患者可以获得血清学应答，因此绝大多数患者需要长期治疗。ETV加用聚乙二醇干扰素 (PEG-IFN)治疗可以增加血清学应答率。

　　美国肝病研究学会（AASLD）第63届年会上,公布了全球性随机临床试验（ARES研究）初步结果。这项随机对照临床试验囊括了欧洲和中国的15个研究中心共纳入了184 例HBeAg 阳性代偿性肝病患者，并分配至ETV单药治疗48周，0.5 mg/d患者组或ETV单药治疗24 周后再联合PEG-IFN α-2a 180 ug/w治疗24周患者组。48周时评估治疗应答(HBeAg 消失伴HBV DNA <200 IU/mL)获得应答的患者经过24周的巩固治疗后（72周）停药，并随访至96 周。目前展示的是治疗48周时的结果。

　　该研究中共177例患者接受了治疗，93例接受ETV单药治疗，84例接受ETV加用PEG-IFN治疗。亚洲族裔的患者占61%，HBV基因型A/B/C/D的比例分别为7 /19 42/32%。到2012年6月，共计160例患者治疗已达48 周，其余患者2个月内也会完成。除HBsAg外，患者在基线时的一些重要的指标具有可比性。接受联合治疗的患者HBsAg水平较高(4.28 对4.03 log IU/mL，P = 0.05）。加用PEG-IFN患者组的应答率以及HBeAg消失率合为18%，而ETV单药治疗的患者组为8% (P = 0.07)。治疗48时加用PEG-IFN患者组HBV DNA (6.33对5.91 log IU/mL，P = 0.05），HBeAg (1.99对1.56 log IU/mL，P = 0.01) 和HBsAg (与 0.32 0.84 登录 IU/mL，P <0.001）的水平下降更为显著。48周时仅一例患者（加用PEG-IFN治疗）获得了HBsAg的清除。校准基线时HBsAg水平后，加用PEG-IFN是治疗48周获得应答的独立相关因素（校准后的优势比：3.63，95 %CI: 1.24-10.7， P = 0.01)。加用PEG-IFN的耐受性好，且相关的副反应也并未增加。

　　研究发现，24周时加用PEG-IFN可促进HBsAg的下降和 HBeAg的清除，并因此有可能增加HBeAg阳性的CHB患者服用ETV获得有限治疗疗程的几率。

　　研究背景：

　　ARES研究，即"Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B"研究，研究注册号NCT00877760，该研究的目的是调查，通过使用暂时加用PEG-IFN策略，是否能增加HBeAg阳性的CHB患者的反应。

　　研究论文摘要：

　　TITLE: Adding peginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg clearance - first results from a global randomized trial (ARES study)

　　Background. Entecavir (ETV) is a potent inhibitor of viral replication in HBeAg-positive chronic hepatitis B (CHB) patients, but serological response is infrequently achieved and indefinite therapy should therefore be anticipated in the majority of patients. Addition of peginterferon (PEG-IFN) to ETV may increase serological response rates.

　　Methods.In this investigator-initiated randomized controlled trial 184 HBeAg-positive patients with compensated liver disease were enrolled at 15 sites in Europe and China and allocated to either ETV 0.5mg daily alone for 48 weeks or a 24 week addition of PEG-IFN alfa-2a 180 ug weekly after 24 weeks of ETV monotherapy. Response (HBeAg loss with HBV DNA <200 IU/mL) was assessed at week 48, and responders were allowed to discontinue treatment after 24 weeks consolidation treatment (week 72), with subsequent off-treatment follow-up until week 96. Results at week 48 are presented here.

　　Results.177 patients received at least one dose of allocated treatment, 93 ETV alone and 84 ETV with PEG-IFN add-on. Sixty-one percent of patients were of Asian ethnicity and all major HBV genotypes were present (A/B/C/D in 7/19/42/32%). A total of 160 patients had reached week 48 by June 2012, and the remaining patients will do so within 2 months. Patients were comparable with regard to important baseline characteristics, except for HBsAg which was higher in patients receiving combination therapy (4.28 versus 4.03 log IU/mL, p=0.05). Response, as well as HBeAg loss alone, was achieved in 18% of patients who received PEG-IFN add-on, compared to 8% of patients treated with ETV alone (p=0.07). PEG-IFN add-on resulted in more decline of HBV DNA (6.33 versus 5.91 log IU/mL, p=0.05), HBeAg (1.99 versus 1.56 log IU/mL, p=0.01) and HBsAg (0.84 versus 0.32 log IU/mL, p<0.001) at week 48. Only one patient (who received PEG-IFN add-on) had clearance of HBsAg at week 48. After adjustment for the differences in baseline HBsAg levels, addition of PEG-IFN was independently associated with response at week 48 (adjusted odds ratio: 3.63, 95% CI: 1.24 – 10.7, p=0.01). Add-on PEG-IFN was well-tolerated and no relevant safety concerns were raised.